

Cerep reports year end and fourth quarter revenues

Rueil-Malmaison, France, 11 February 2000 - Cerep SA (Nouveau Marché, CEREP), the drug discovery company, today announced its consolidated sales for the period ended 31 December 1999.

Cerep reported fourth quarter sales of FF 25.5 million (Euros 3.9 million) which is an increase of 126 % compared to 1998 sales of FF 11.3 million (Euros 1.7 million). For the full year, sales were FF 70.5 million (Euros 10.7 million) an increase of 26 % compared to sales of FF 56.1 million (Euros 8.6 million) a year ago. Cerep expects the loss for 1999 not to exceed FF 32 million (Euros 4.9 million). This figure takes into account FF 8.2 million (Euros 1.3 million) for non-recurring charges resulting primarily from the relocation of its operations.

Cerep has undertaken a strategic cost management program in conjunction with a rationalization of its drug discovery operations by relocating its chemistry operations (Lille, France) and headquarters (Paris, France) to its new research facilities in Rueil-Malmaison.

Commenting on the sales, Thierry Jean, CEO, noted that the increase was attributable to several factors. "A significant contribution to the increase in sales was achieved by our fee-for-service business and through sales of Cerep's high quality and diverse library, Odyssey 5000. Our US subsidiary, Cerep Inc., also secured record sales adding to our sales success. In addition, the multi-year drug discovery agreement secured in October with Bristol-Myers Squibb contributed to our 4th quarter sales, with the bulk of revenues generated from this deal to be collected during 2000. We are confident that our sales performance over the 4th quarter 1999 will continue into 2000."

Concurrently, Cerep announced that it has attracted FF 6 million (Euros 0.9 million) in funding from ANVAR (Agence Nationale de la Valorisation de la Recherche), the French agency responsible for promoting and financing innovation, in the form of interest free loans which are designated for Cerep's database BioPrint™ product.

BioPrint™ database is a rapidly growing data resource that relates chemical structure, *in vitro* test results and *in vivo* activities for the purpose of designing drug-like properties into a molecule.

Included in the BioPrint™ database are data on marketed drugs, subscriber reference compounds and compounds proprietary to BioPrint™ subscribers. Under the terms of drug discovery agreement signed with Bristol-Myers Squibb on 20 October 1999 Cerep's newest collaborative partner became the first subscriber to BioPrint™.

In addition Cerep has been granted the Eureka Label for its research program in the area of HIV being carried out in collaboration with the Belgian pharmaceutical firm, Tibotec. This project will also be entitled to a new ANVAR grant.

Cerep is a drug discovery company that focuses on finding new and effective drugs. The Company's mission is to develop integrated technologies and tools to overcome the current obstacles and challenges of the drug discovery process. Cerep assists pharmaceutical companies by incorporating all the facets of innovative technologies for the discovery of novel and effective drugs. In Europe and North America, the Company has developed an extensive R&D capacity in the areas of High Throughput screening, pharmacological and pharmaceutical profiling and High Throughput organic synthesis and computational chemistry. Cerep has a unique business model combining revenue generating drug discovery services with strategic collaborations in drug discovery.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.